ILXQuant Orphan Disease and Gene Therapy Basket Index
Fixed-basket index of 10 companies targeting the 7,000-plus rare diseases that affect 300 million people globally -- of which 95 percent have no approved treatment. FDA Orphan Drug Designation grants 7 years of market exclusivity plus Priority Review Vouchers worth $100M-plus. Pricing power reaches $500K to $4M per patient per year because the alternative is death. The basket spans Duchenne muscular dystrophy gene therapy (Sarepta, $3.2M per dose), rare metabolic diseases (Ultragenyx), enzyme replacement (Amicus), prion-like protein disease (Prothena), oncolytic virotherapy (Replimune), AAV gene therapy (Voyager), topical gene therapy for skin blistering (Krystal Biotech), rare liver disease (Akero), rare inflammation (AnaptysBio), and drug delivery enabling all of the above (Halozyme ENHANZE platform). Rebalances quarterly to equal weight.
- Index identifier
- ILXRRD
- Category
- Basket
- Universe
- Fixed basket -- 10 orphan disease and gene therapy companies (equal weight)
- Currency
- USD
- Inception
- 2020-03-02
- Rebalancing
- Quarterly (first Monday of March, June, September, December)
- Index fee
- 0.60% p.a.
- Reference benchmark
- Health Care SPDR (XLV)
Performance and risk
All figures below are measured over a trailing window of up to 1,260 trading days (approximately five years), not since index inception.
| Annualised return | +9.13% |
|---|---|
| Sharpe ratio | 0.23 |
| Calmar ratio | 0.23 |
| Volatility | 38.91% |
| Maximum drawdown | -39.98% |
| Return, 1 month | — |
| Return, 3 months | — |
| Return, 1 year | — |
| Return, year to date | -4.74% |
Full performance history, drawdown analysis, rolling risk metrics and portfolio breakdowns for this index are available in the ILX Quant platform.